Dr. Richard Isaacson was featured by The Wall Street Journal discussing how access to newly approved Alzheimer’s disease treatments can vary significantly depending on where a patient lives. As disease-modifying therapies become available, he explained that timely access depends not only on FDA approval but also on the availability of specialized memory clinics, infusion centers, biomarker testing, and clinicians experienced in diagnosing and treating early Alzheimer’s disease.

Dr. Isaacson emphasized that these treatments require careful patient selection and comprehensive evaluation, including confirmation of Alzheimer’s pathology through biomarkers and ongoing safety monitoring. He noted that geographic differences in healthcare infrastructure can create disparities in access, highlighting the need to expand specialized Alzheimer’s care so more eligible patients can benefit from advances in precision medicine and early intervention.

Read the full The Wall Street Journal article to learn how access to new Alzheimer’s therapies may differ across the United States and what it means for patients and families.